| Literature DB >> 24106423 |
Anna Norweg1, Eileen G Collins.
Abstract
BACKGROUND: Dyspnea is a complex, prevalent, and distressing symptom of chronic obstructive pulmonary disease (COPD) associated with decreased quality of life, significant disability, and increased mortality. It is a major reason for referral to pulmonary rehabilitation.Entities:
Keywords: anxiety; chronic obstructive pulmonary disease; distractive auditory stimuli; dyspnea; self-management; slow breathing
Mesh:
Year: 2013 PMID: 24106423 PMCID: PMC3791959 DOI: 10.2147/COPD.S30145
Source DB: PubMed Journal: Int J Chron Obstruct Pulmon Dis ISSN: 1176-9106
Dyspnea assessments used in review studies
| Instrument name | Constructs | MCID |
|---|---|---|
| Borg Breathlessness Scale (Borg) | Dyspnea intensity | 1.0 unit |
| Borg Dyspnea Distress Scale (BorgDD) | Dyspnea distress | 1.0 unit |
| Breathlessness Beliefs Questionnaire | Dyspnea-related anxiety: somatic and activity avoidance beliefs | Not known |
| Chronic Respiratory Disease Questionnaire (CRQ) | Dyspnea intensity with activities (dyspnea scale, CRQ-D); dyspnea-related anxiety (mastery scale, CRQ-M) | 0.5 per item |
| COPD Self-Efficacy Scale (CSES) | Dyspnea self-efficacy | Not known |
| Dyspnea Management Questionnaire (DMQ) | Dyspnea intensity with activities; dyspnea-related anxiety; activity avoidance; self-efficacy | Not known |
| Interpretation of Breathing Problems Questionnaire (IBPQ) | Dyspnea-related anxiety; catastrophic thoughts | Not known |
| Modified Medical Research Council Dyspnea Scale (mMRC) | Dyspnea impact or burden | Not known |
| Self-Efficacy for Managing Shortness of Breath (SEMSOB) | Dyspnea self-efficacy | Not known |
| St George’s Respiratory Questionnaire (SGRQ) | Dyspnea impact or burden (activity scale: SGRQ-A) | 4 units |
| Transition Dyspnea Index (TDI) | Dyspnea impact or burden | 1.0 unit |
| University of California, San Diego Shortness of Breath Questionnaire (SOBQ) | Dyspnea intensity with activities | 5 units |
| Visual Analog Scale – Unpleasantness (VAS-U) | Dyspnea affect | 10–20 units |
| Visual Analog Scale – Dyspnea Distress (VAS-DD), Dyspnea | Dyspnea distress; dyspnea-related anxiety; dyspnea intensity | 10–20 units |
| Anxiety (VAS-DA), shortness of breath (VAS-SOB) | ||
Abbreviations: MCID, minimal clinical important difference; COPD, chronic obstructive pulmonary disease; D, dyspnea scale; M, mastery scale; A, activity scale.
Meditation studies
| Study | Design/treatment | N | FEV1 % predicted M ± SD | Group | Dyspnea score: short-term, M (SD) | Effect size | MCID | Dyspnea score: long-term (6 month follow up), M (SD) |
|---|---|---|---|---|---|---|---|---|
| Donesky-Cuenco et al | RCT; 1 hour, twice weekly; 12 weeks | 14 | 51.2 ± 10.5 | E: Yoga | E: 3.8 (2.3)–3.8 (1.5)Borg6MW | 0.2 | X | |
| 15 | 44.4 ± 19 | C: Usual care | C: 2.9 (1.6)–3.3 (2.5) | X | ||||
| E:2.6 (2.8)–1.6(1.7)BorgDD
| 0.67 | √ | ||||||
| C: 1.1 (1.1)–1.4 (1.5) | X | |||||||
| E: 14.6 (3.0)–16.8 (6.3) CRQ-D | 0.07 | X | ||||||
| C: 12.9 (6.1)–15.2 (6.6) | X | |||||||
| E: 22.4 (3.5)–22.3 (4.0) CRQ-M | 0.07 | X | ||||||
| C: 19.5 (5.0)–19.4 (5.3) | X | |||||||
| Yeh et al | RCT; 1 hour twice weekly; 12 weeks | 5 | 53 ± 7 | E: Tai chi | E: 4.4–5.7 CRQ-D | √mod | ||
| 5 | 47 ± 7 | C: Usual care | C: 6.0–6.4 | X | ||||
| E: 4.2–6.5 CRQ-M | √large | |||||||
| C: 6.0–5.7 | X | |||||||
| E: 39–27 UCSD | √ | |||||||
| C:20–22 | X | |||||||
| E: 105–135 CSES | ||||||||
| C: 135–137 | ||||||||
| Chan et al | RCT; TCQ: 1 hour twice weekly for 3 months(br/)Measures: 0, 6 weeks, 3 months | 60 | Data not available | E:TCQ | E: 1.98 (1.21)–1.84 (1.38)6wk–1.86 (1.25)3m Borg6MW | −0.11 | X | |
| 50 | C1: BT | −0.1 | ||||||
| 48 | C2: Control | C1: 1.38 (1.74)–1.74(1.37)–1.70 (1.38) | 0.23, 0.20 | X | ||||
| C2: 1.51 (1.43)–2.02(1.50)–2.06(1.53) | X | |||||||
| Ng et al | RCT; one 45-minute session; 4 weeks | 23 | 37.1 ± 2.2 | E: TCQ + PR | Not reported | E: 0.64 (0.26 SE) CRQ-D6m | ||
| 29 | 36.8 ± 2.1 | C: PR alone | C: 0.26 (0.21) | |||||
| E: 0.64 (0.29) CRQ-M | ||||||||
| C: 0.33 (0.20) | ||||||||
| Mularski et al | RCT; once-weekly group MBBT, 8 weeks; support group, matched time; diary | 20 | Data not available | E: MBBT | E: 4.6–4.3 Borg6MWT | X | ||
| 29 | C: Support group | C: 4.6–4.6 | X | |||||
| E: 26.4 VAS (at rest) | ||||||||
| C: 27.9 | ||||||||
| E: 50.7 VAS (dyspnea activity) | ||||||||
| C: 49.3 | ||||||||
| E: 68.6–71.2 SGRQ-A | X | |||||||
| C: 69.4–69.8 | X | |||||||
| Katiyar and Bihari | RCT; 3-month training | 24 | 48 ± 2.4 | E: Yoga breathing | E: 66 (2.1)–50 (1.7) SGRQ-A | −8.37 | √ | |
| 24 | 48 ± 2 | C: Control | C: 63–62 | X |
Notes:
P < 0.01 for within-group mean change;
P = 0.07–0.08.
Abbreviations: Borg, modified Borg scale; BT, breathing training; C, control or comparison group; CRQ-D, Chronic Respiratory Disease Questionnaire, dyspnea subscale; CRQ-M, Chronic Respiratory Disease Questionnaire, mastery scale; CSES, COPD Self-Efficacy Scale; DD, dyspnea distress; E, experimental group; FEV1 forced expiratory volume in 1 second; m, months; M, mean; MBBT, mindfulness-based breathing therapy; MCID, minimal clinical important difference; mod, moderate; PR, pulmonary rehabilitation; RCT, randomized controlled trial; SD, standard deviation; SE, standard error; SGRQ-A, St George’s Respiratory Questionnaire, activity scale; TCQ, Tai Chi Qigong; UCSD, University of California, San Diego, Shortness of Breath Questionnaire; VAS, visual analog scale; wk, weeks; 6MW, 6-minute walk distance (feet); √, exceeded MCID; X, did not meet MCID.
Cognitive-behavioral therapy studies
| Study | Design/intervention | N | FEV1% predicted, M ± SD | Group | Dyspnea score; short-term, M (SD) | Effect size | MCID | Dyspnea score; long-term (6–18 month), M (SD) | Effect size |
|---|---|---|---|---|---|---|---|---|---|
| Livermore et al | RCT; Indiv CBT, post-PR, 1 hour once per week, 4 weeks | 21 | 57.0 ± 25.1 | E: CBT | E: 7.0 (4.3) IBPQwk4 | IBPQ6m | |||
| 20 | 51.1 ± 15.0 | C: Usual care | C: 8.2 (4.8) | ||||||
| Kunik et al | RCT; 1 hour per week, 8 weeks; CBT delivered in groups of up to ten patients | 1 18 | 45.3 ± 16.8 | E: CBT | E: 2.99 (1.33)–3.36 (1.64) | 0.25 | X | E: 2.99(1.33)–3.38 (1.96)12m | 0.23 |
| 120 | 46.8 ± 17.5 | C: COPD educ | C: 3.11 (1.53)–3.51 (3.04) | 0.17 | X | CRQ-D | 0.28 | ||
| E: 4.00 (1.83)–4.47 (1.82) | 0.26 | X | C: 3.11 (1.53)–3.60 (1.91) | 0.34 | |||||
| C: 3.95 (1.85)–4.37 (1.82) | 0.23 | X | E: 4.00 (1.83)–4.62 (1.82) CRQ-M | 0.23 |
Notes:
P < 0.01 favoring treatment group;
P < 0.01 for within-group mean change.
Abbreviations: C, control or comparison group; CBT, cognitive–behavioral therapy; COPD, chronic obstructive pulmonary disease; CRQ-D, Chronic Respiratory Disease Questionnaire, dyspnea scale; CRQ-M, Chronic Respiratory Disease Questionnaire, mastery scale; E, experimental group; educ, education; FEV1 forced expiratory volume in 1 second; IBPQ, Interpretation of Breathing Problems Questionnaire; Indiv, individual; m, months; M, mean; MCID, minimal clinical important difference; PR, pulmonary rehabilitation; RCT, randomized controlled trial; SD, standard deviation; wk, weeks; √, exceeded MCID; X, did not meet MCID.
Breathing studies
| Study | Design/intervention | N | FEV1 % predicted, M ± SD | Group | Dyspnea score; short-term, M (SD) | Effect size | MCID | Dyspnea score; long-term (2–3 months), M (SD) | Effect size |
|---|---|---|---|---|---|---|---|---|---|
| Yamaguti et al | RCT, pre-post-test; 3 indiv 45-minute weekly sessions, 4 weeks | 15 | 43.4 | E: DBT | E: 2.6–2.0 | −0.41 (b/w group) | |||
| 15 | 42.4 | C: Control | C: 2.8–2.5 mMRC | ||||||
| Nield et al | RCT; 0, 4 week, 3 monthly; 4-weekly training sessions | 53 | 38 ± 14 | E: PLB | VAS | Borg6MW 3m | |||
| C1: IMT | UCSD | ||||||||
| C2: EMT | Borg | ||||||||
| C: Control | |||||||||
| Nield et al | RCT; 0, 4-, 12-week time points; weekly monitored breathing sessions in laboratory and daily home practice for 4 weeks | 14 | 35 ± 8 | E1: PLB | E1: 3.9 (1.3)–3.2 (0.9) Borg | −0.63 | X | E1: 3.9 (1.3)–3 (1.0) | −0.78 |
| 13 | 43 ± 16 | E2: EMT | E2: 4.2 (0.9)–3.7 (0.7) | −0.62 | X | E2: 4.2 (0.9)–3.9 (0.7) | −0.37 | ||
| 13 | 40 ± 15 | C: Control | C: 3.8 (0.7)–3.2 (0.8) | −0.80 | X | C: 3.8 (0.7)–4 (1.4) | 0.18 | ||
| E1: 68 (24)–60 (16) UCSD | −0.39 | √ | E1: 68(24)–59 (I7) UCSD | −0.43 | |||||
| E2:65 (19)–63 (18) | −0.11 | X | E2: 65 (19)–68 (22) | 0.15 | |||||
| C: 58 (28)–64 (20) | 0.25 | √worse | C: 58 (28)–69 (24) | 0.42 | |||||
| Collins et al | RCT; 36 ET training sessions; VF with monitor display of RR and goal | 17 | 41 ± 18 | E: VF + PR | 5.6 (4.1)–1.3 (1.4) | −1.40 | √ | ||
| 16 | 43 ± 15 | C1: PR alone | 6.2 (3.8)–2.2 (2.4) | −1.26 | √ | ||||
| 16 | 46 ± 16 | C2: VF alone | 5.7 (3.0)–3.3 (2.8) | −0.83 | √ | ||||
| E: +4 (6) CRQ-D | |||||||||
| C1: +6(5) | |||||||||
| C2: +6 (5) | |||||||||
| E: 3 (3) | |||||||||
| C1: NR/NS | |||||||||
| C2: NR/NS | |||||||||
| Bonilha et al | RCT; 24, 1 hour weekly group training classes; 24 weeks | 15 | 48.8 ± 20.8 | E: Singing | E: 0.7 (1.2) TDI | X | |||
| 15 | 53.4 ± 20.1 | C: Handcraft | C: 0.3 (1.7) | X | |||||
| van Gestel et al | RCT; 4-week PR program; 10 × 30-minute VF sessions; PLB and DB | 20 | 47.0 ± 19.9 | E: VF + PR | E: 0.88 (0.74) CRQ-D | √ | |||
| 20 | 44.3 ± 17.3 | C: PR | C: 0.57 (LOI) | √ | |||||
| E: 0.62 (0.97) CRQ-M | √ | ||||||||
| C: 0.45 (0.90) | X | ||||||||
| E: −0.1 (1.0) BorgPost-6MW | X | ||||||||
| C: 0.3 (1.7) | X | ||||||||
| Scherer et al | RCT; twice daily 15 minutes, 5 days/week, 8 weeks | 15 | 50.2 ± 4.4 | E: RMT | E: 4.7 TDI | √ | |||
| 15 | 52.3 ± 3.5 | C: BT | C: 2.9 | √ |
Notes:
P < 0.05, favoring experimental/treatment group;
P < 0.05 for within-group mean change;
P < 0.01 for within-group mean change;
P = 0.05.
Abbreviations: Borg, modified Borg scale 0–10 point; BT, breathing training; C, control or comparison group; CRQ-D, Chronic Respiratory Disease Questionnaire, dyspnea scale; CRQ-M, Chronic Respiratory Disease Questionnaire, mastery scale; DB, diaphragmatic breathing; DBT, diaphragmatic breathing training; E, experimental group; ET, exercise training; EMT, expiratory muscle training; FEV1 forced expiratory volume in 1 second; indiv, individualized; IMT, inspiratory muscle training; m, months; min, minutes; M, mean; MCID, minimal clinical important difference; mMRC, modified Medical Research Council scale; NR, not reported; NS, not significant; PLB, pursed-lips breathing; PR, pulmonary rehabilitation; RCT, randomized controlled trial; RMT, respiratory muscle endurance training; SD, standard deviation; TDI, Transition Dyspnea Index; TET, treadmill exercise test; UCSD, University of California, San Diego Shortness of Breath Questionnaire; VAS, visual analog scale; VE, vocalization exercises; VF, ventilation feedback training; 6MW, 6-Minute Walk Test; √, exceeded MCID; X, did not meet MCID; b/w, between; RR, respiratory rate.
Dyspnea self-management studies
| Study | Design/intervention | N | FEV1 % predicted, M ± SD | Group | Dyspnea score; post-intervention (short-term), M (SD) | Effect size | MCID | Dyspnea score; long-term (2- to 12-month follow up), M (SD) | Effect size |
|---|---|---|---|---|---|---|---|---|---|
| Stulbarg et al | RCT; D-SM: 3 hours of indiv educ and indiv HEP with pedometer and daily log measurement: 0 and 2 months | 36 | 42.5 ± 18.4 | C1: D-SM | C1: 16.0 (5.6)–17.7 (5.5) CRQ-D | 0.31 | X | ||
| 33 | 48.5 ± 12.6 | C2: D-SM + Ex4 | C2: 17.4 (4.2)–21.1 (5.3) | 0.77 | √small | ||||
| 34 | 43.7 ± 9.9 | E: D-SM + Ex24 | E: 15.8 (4.9)–20.8 (4.5) | 1.06 | √mod | ||||
| C1: 5.1 (1.4)–1.5 (2.5) TDI | √ | ||||||||
| C2: 5.4 (1.4)–1.5 (2.7) | √ | ||||||||
| E: 4.9(1.7)–2.0(2.2) | √ | ||||||||
| C1: 53.3 (17.7)–51.6 (15.6) UCSD | −0.10 | X | |||||||
| C2:50.6(18.0)–46.1 (17.5) | −0.25 | X | |||||||
| E: 54.7 (15.1)–52.4 (16.7) | −0.14 | X | |||||||
| C1: 18.6 (5.3)–20.3 (4.7) | 0.34 | X | |||||||
| C2: 19.9 (4.6)–21.8 (4.9) | 0.40 | X | |||||||
| E: 17.9 (4.9)–22.6 (4.1) | 1.04 | √mod | |||||||
| C1: 4.7 (2.0)–4.4 (1.6)BorgITT | −0.17 | X | |||||||
| C2: 4.9 (2.3)–4.2 (2.4) | −0.30 | X | |||||||
| E: 4.8 (1.8)–3.0 (1.3) | −1.15 | √ | |||||||
| C1: 3.8 (1.8)–3.9 (2.0)Borg6MW | 0.05 | X | |||||||
| C2: 4.0 (1.9)–3.3 (1.9)* | −0.37 | X | |||||||
| E: 4.7 (2.6)–3.4 (1.4) | −0.62 | √ | |||||||
| Carrieri-Kohlman et al | RCT; 12 Ex sessions over 4–6 weeks; 8 weeks of home walking with pedometer; 0, 4–6 wks; 8-week follow up | 24 | 40 ± 11 | E: D-SM + Ex12 | E: 4.8 (1.1)–5.3 (1.5) | 0.38 | √ | E: 4.8–5.9 (1.6)+CRQ-D8wk | 0.80 |
| 27 | 36 ± 10 | C: Ex12 only | C: 5.1 (1.1)–5.8 (1.6) | 0.51 | √ | C: 5.1 (1.1)–5.7 (1.7) | 0.42 | ||
| E: 142 (58)–97 (64) | −0.74 | √ | |||||||
| C: 155 (42)–78 (55) | −1.57 | √ | |||||||
| E: 113 (67)–72 (65) | −0.62 | √ | |||||||
| C: 133 (62)–49 (49) | −1.50 | √ | |||||||
| E: 97 (76)–50 (60) | −0.69 | √ | |||||||
| C: 110 (76)–42 (51) | −1.05 | √ | |||||||
| 220 mm VAS | [MCID 20 mm] | ||||||||
| Carrieri-Kohlman et al | RCT; repeated measures: 0, every 2 months for 1 year; either 4 or 24 Ex sessions; SM: four 1 hour and two ½ hr (4 month, 8 month) indiv sessions, home walking, biweekly telephone calls | 36 | 44.8 ± 1.4 (for total) | C1:D-SM | C1: 16(0.8)–1.7Δ, | C1: X | C1: 16–4.5 | ||
| 33 | C1: D-SM + Ex4 | C2: 17.2 (0.8)–3.7 | C2: √small | C2: 17.2–4.2 | |||||
| 34 | E: D-SM + Ex24 | E: 15.8 (0.8)–5.0 | E: √mod | E: 15.8–3.2 | |||||
| C1: 18.4 (0.8)–1.8Δ CRQ-M | C1: X | C1: 18.4–2.5 | |||||||
| C2: 19.9 (0.8)–1.9Δ | C2: X | C2: 19.9–1.4 | |||||||
| E: 17.9 (0.8)–4.7 | E: √mod | E: 17.9–1.6 | |||||||
| C1: 0.5(0.1)–0Δ BorgITT | X | C1: 0.5 to −0.1 BorgITT,12m | |||||||
| C2: 0.5(0.1)–0Δ | X | C2: 0.5–0.1 | |||||||
| E: 0.6(0.1)to−0.2 | X | E: 0.6 to −0.2 | |||||||
| Davis et al | RCT: same as for Stulbarg et al | 36 | 44 ± 19 | C1: D-SM | C1: 2.97 (0.69)–2.98 (0.63) CSES | 0.02 | |||
| 32 | 49 ± 13 | C1: D-SM + Ex4 | C2: 3.28 (0.70)–3.26 (0.81) | −0.3 | |||||
| 34 | 44 ± 10 | E: D-SM + Ex24 | E: 3.10 (0.92)–3.22 (0.85) | 0.14 | |||||
| C1: 4.44 (2.5)–5.7 (2.2) | 0.54 | ||||||||
| C2: 5.7 (2.6)–6.5 (2.5) | 0.31 | ||||||||
| E: 6.1 (2.7)–7.0 (2.4) | 0.35 | ||||||||
| Nguyen et al | RCT; repeated measures: 0, 3 month, 6 month | 20 | 50.3 ± 17.6 | C: fD-SM | C: 15.9 (5.4)–19.2 (5.8)–19.9 (6.2) | 0.59/0.69 | √/√ | ||
| 19 | 49.0 ± 16.8 | E: eD-SM | CRQ-D | ||||||
| E: 18.8 (6.2)–22.3 (4.6)–21.3 (6.0) | 0.64/0.41 | √/√ | |||||||
| C: 20.4 (5.2)–22.3 (5.8)–22.4 (5.5) | 0.34/0.37 | X/√ | |||||||
| CRQ-M | |||||||||
| E: 21.7 (3.2)–23.6 (2.9)–23.6 (3.7) | 0.62/0.55 | X/X | |||||||
| C: 4.6 (2.4)–5.5 (3.3)–5.0 (3.6) CSES | 0.31/0.13 | ||||||||
| E: 4.7 (2.3)–6.8 (2.3)–6.7 (2.6) | 0.91/0.81 |
Notes:
P < 0.05, favoring treatment group:
P < 0.01 favoring treatment group:
P < 0.05 for within-group mean change:
P < 0.01 for within-group mean change.
Abbreviations: Ex, exercise sessions: Borg, modified Borg scale; C, control or comparison group; CRQ-D, Chronic Respiratory Disease Questionnaire, dyspnea scale; CRQ-M, Chronic Respiratory Disease Questionnaire, mastery scale; CSES, COPD Self-Efficacy Scale; D-SM, dyspnea self-management E, experimental group; eD-SM, Internet-based dyspnea self-management; educ, education; fD-SM, face-to-face dyspnea self-management; FEV1, forced expiratory volume in 1 second; HEP, home exercise program; indiv, individualized; ITT, incremental treadmill test (isotime); m.months; M, mean; MCID, minimal clinical important difference; mod, moderate; RCT, randomized controlled trial; SD, standard deviation; SEMSOB, Self-Efficacy for Managing Shortness of Breath; SM, self-management; SOB, shortness of breath; TDI, Transition Dyspnea Index TST, treadmill stress test; UCSD, University of California, San Diego Shortness of Breath Questionnaire; VAS, 100 mm visual analog scale; VAS-DA, visual analog scale – dyspnea anxiety; VAS-DD, visual analog scale – dyspnea distress; wk, weeks; 6MVV, 6-Minute Walk Test; Δ, difference score; √, exceeded MCID; X, did not meet MCID.
Distractive auditory stimulus (DAS/music) studies
| Study | Design/intervention | N | FEV1% predicted, M ± SD | Group | Dyspnea score; short-term, M (SD) | MCID | Effect size |
|---|---|---|---|---|---|---|---|
| Singh et al | RCT; pre-post-test design; 30 minutes, twice on same day; PMR pre-recorded; inpatient intervention | 32 | 49 ± 11 | E: Music | E: 49.1 (17.1)pre1−34.7 (14.3)post1 VAS | √ | −0.91 |
| 32 | 54 ± 11 | C: PMR | C: 46 (13)pre1–38.4 (14.6)post1 | X | −0.55 | ||
| E: 47 (16.2)pre2–23.9 (10.2)post2
| √ | −1.71 | |||||
| C: 45.4 (11.3)pre2–32.5 (14.4)post2 | √ | −1.0 | |||||
| Bauldoff et al | RCT; repeated measures: 0, 4, 8 weeks; post-PR, home walking program with DAS and electronic pedometer/log; Music: 90–110 bpm | 12 | 40.4 ± 15.6 | E: DAS (music) | E: 60.2–52.2–44.28wks
| √4, 8wks | |
| 12 | 42.3 ± 10.5 | C: HEP only | C: 45.5–47.1–53.3 | √worse, 8wks | |||
| E: 2.9 (1.2)–3.3 (1.2)–3.0 (1.2) Borg6MW | X | E: 0.33, 0.08 | |||||
| C: 3.6 (1.1)–3.2 (1.1)–3.2 (0.8) | X | C: −0.36, −0.42 | |||||
| E: 63.8 (24.2)–65.9 (23.3)–67.8 (19.9) SGRQ-A | √worse, 8wks | E: 0.09, 0.18 | |||||
| C: 62.0 (19.9)–61.5 (17.8)–64.3 (16.1) | X | C: −0.03, 0.13 | |||||
| Bauldoff et al | RCT; post-PR; UET sessions 15 minutes, 2–3 times/week for 4 weeks; portable music | 10 | 33.8 ± 16.3 | E1: UET + DASMod | E1: 65.8 (21.8)–62.3 (18.5) UCSD4wks | X | −0.17 |
| 10 | 41.3 ± 17.8 | E2: UET + DASSlow | E2: 58.4 (22.9)–53.9 (22.3) | X | −0.20 | ||
| 10 | 46.1 ± 19.9 | C: UET | C: 55.2 (22.8)–54.0 (16.7) | X | −0.06 | ||
| E1: 78.8 (10.5)–72.3 (16.7) SGRQ-A | √ | −0.47 | |||||
| E2: 77.7 (15.9)–68.3 (15.1) | √ | −0.61 | |||||
| C: 79.4 (15.6)–76.8 (15.7) | X | −0.17 |
Notes:
P < 0.05, favoring treatment group;
P < 0.01 favoring treatment group.
Abbreviations: Borg, modified Borg scale; bpm, beats per minute; C, control or comparison group; DAS, distractive auditory stimuli; E, experimental group; FEV1, forced expiratory volume in 1 second; HEP, home exercise program; M, mean; mod, moderate; MCID, minimal clinical important difference, PMR, progressive muscle relaxation; postx, post session x; PR, pulmonary rehabilitation; prex, pre session x; RCT, randomized controlled trial; SD, standard deviation; SGRQ-A, St George’s Respiratory Questionnaire, activity scale; UCSD, University of California, San Diego Shortness of Breath Questionnaire; UET, upper extremity training exercises using upper body ergometry; VAS, 100 mm visual analog scale; 6MW, 6-Minute Walk Test, meters; √, exceeded MCID; X, did not meet MCID.